Cargando…

Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study

Background. The so-called “vaccine hesitancy” still represents a common phenomenon that undermines the effectiveness of vaccination campaigns. In 2020, the Italian Medicines Agency recommended to bring forward the flu vaccination campaign, whose importance was also emphasized for patients with Multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziello, Antonio, Scavone, Cristina, Di Battista, Maria Elena, Salvatore, Simona, Di Giulio Cesare, Daniele, Moreggia, Ornella, Allegorico, Lia, Sagnelli, Anna, Barbato, Stefano, Manzo, Valentino, Capuano, Annalisa, Maniscalco, Giorgia Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301852/
https://www.ncbi.nlm.nih.gov/pubmed/34356125
http://dx.doi.org/10.3390/brainsci11070890
_version_ 1783726767149678592
author Ziello, Antonio
Scavone, Cristina
Di Battista, Maria Elena
Salvatore, Simona
Di Giulio Cesare, Daniele
Moreggia, Ornella
Allegorico, Lia
Sagnelli, Anna
Barbato, Stefano
Manzo, Valentino
Capuano, Annalisa
Maniscalco, Giorgia Teresa
author_facet Ziello, Antonio
Scavone, Cristina
Di Battista, Maria Elena
Salvatore, Simona
Di Giulio Cesare, Daniele
Moreggia, Ornella
Allegorico, Lia
Sagnelli, Anna
Barbato, Stefano
Manzo, Valentino
Capuano, Annalisa
Maniscalco, Giorgia Teresa
author_sort Ziello, Antonio
collection PubMed
description Background. The so-called “vaccine hesitancy” still represents a common phenomenon that undermines the effectiveness of vaccination campaigns. In 2020, the Italian Medicines Agency recommended to bring forward the flu vaccination campaign, whose importance was also emphasized for patients with Multiple Sclerosis (MS). We aimed to assess vaccination behavior in patients with MS to prepare for the upcoming SARS-CoV-2 vaccination challenge. Methods. This is an observational study carried out in one MS clinical Centre that enrolled all MS patients who were eligible for any of the flu vaccines recommended by the Italian medicines Agency. Results. 194 patients were enrolled. Patients’ mean age was 43.9 years and 66% were female. Comorbidities, mainly represented by non-autoimmune diseases, were identified in 52% of patients. Almost all patients were receiving a DMT during the study period, mainly dimethyl fumarate, natalizumab, teriflunomide, and interferon. Out of 194 patients, 58.2% accepted to be vaccinated. No statistically significant differences were found, except for the use of natalizumab, which was higher among vaccinated patients. Conclusion. The results of our study emphasize the importance of education and communication campaigns addressed both to healthcare providers and patients with MS, especially considering that MS patients are currently receiving COVID-19 vaccinations.
format Online
Article
Text
id pubmed-8301852
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83018522021-07-24 Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study Ziello, Antonio Scavone, Cristina Di Battista, Maria Elena Salvatore, Simona Di Giulio Cesare, Daniele Moreggia, Ornella Allegorico, Lia Sagnelli, Anna Barbato, Stefano Manzo, Valentino Capuano, Annalisa Maniscalco, Giorgia Teresa Brain Sci Article Background. The so-called “vaccine hesitancy” still represents a common phenomenon that undermines the effectiveness of vaccination campaigns. In 2020, the Italian Medicines Agency recommended to bring forward the flu vaccination campaign, whose importance was also emphasized for patients with Multiple Sclerosis (MS). We aimed to assess vaccination behavior in patients with MS to prepare for the upcoming SARS-CoV-2 vaccination challenge. Methods. This is an observational study carried out in one MS clinical Centre that enrolled all MS patients who were eligible for any of the flu vaccines recommended by the Italian medicines Agency. Results. 194 patients were enrolled. Patients’ mean age was 43.9 years and 66% were female. Comorbidities, mainly represented by non-autoimmune diseases, were identified in 52% of patients. Almost all patients were receiving a DMT during the study period, mainly dimethyl fumarate, natalizumab, teriflunomide, and interferon. Out of 194 patients, 58.2% accepted to be vaccinated. No statistically significant differences were found, except for the use of natalizumab, which was higher among vaccinated patients. Conclusion. The results of our study emphasize the importance of education and communication campaigns addressed both to healthcare providers and patients with MS, especially considering that MS patients are currently receiving COVID-19 vaccinations. MDPI 2021-07-05 /pmc/articles/PMC8301852/ /pubmed/34356125 http://dx.doi.org/10.3390/brainsci11070890 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ziello, Antonio
Scavone, Cristina
Di Battista, Maria Elena
Salvatore, Simona
Di Giulio Cesare, Daniele
Moreggia, Ornella
Allegorico, Lia
Sagnelli, Anna
Barbato, Stefano
Manzo, Valentino
Capuano, Annalisa
Maniscalco, Giorgia Teresa
Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
title Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
title_full Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
title_fullStr Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
title_full_unstemmed Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
title_short Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
title_sort influenza vaccine hesitancy in patients with multiple sclerosis: a monocentric observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301852/
https://www.ncbi.nlm.nih.gov/pubmed/34356125
http://dx.doi.org/10.3390/brainsci11070890
work_keys_str_mv AT zielloantonio influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT scavonecristina influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT dibattistamariaelena influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT salvatoresimona influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT digiuliocesaredaniele influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT moreggiaornella influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT allegoricolia influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT sagnellianna influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT barbatostefano influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT manzovalentino influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT capuanoannalisa influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy
AT maniscalcogiorgiateresa influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy